Cancer Research and Treatment

Original Articles

Prognostic Performance of the Next-Generation Sequencing-Based Multigene Assay in Early Breast Cancer Patients Treated According to the 21-Gene Assay Results: Eunhye Kang, Jong-Ho Cheun, Jeeyeon Lee, Jiwon Koh, Hyunwoo Lee, Ji-Young Park, Hee Jin Lee, Byeongju Kang, Woong Ki Park, Jeongeun Son, Bumjoon Kim, Woosung Chung, Wonshik Han, Han-Byoel Lee, Sae Byul Lee, Jai Min Ryu; Received October 28, 2024 Accepted December 22, 2024 Published online December 23, 2024; DOI: https://doi.org/10.4143/crt.2024.1035 [Accepted]

Abstract PDF: Purpose
Multigene assays guide treatment decisions in early-stage hormone receptor-positive breast cancer. OncoFREE, a next-generation sequencing assay using 179 genes, was developed for this purpose. This study aimed to evaluate the concordance between the Oncotype DX (ODX) Recurrence Score (RS) and the OncoFREE Decision Index (DI) and to compare their performance.
Materials and Methods
We retrospectively collected tumor blocks from patients who underwent ODX and treatment between 2012 and 2022 at four tertiary hospitals and performed OncoFREE on these samples. Distant metastasis-free survival (DMFS) was compared using RS and DI, with score cut-offs of 25 and 20, respectively.
Results
Among 838 patients, a strong correlation was observed between RS and DI (Pearson correlation coefficient 0.83). At a median follow-up of 54 months, patients with high DI had significantly worse DMFS compared to those with low DI (log-rank p < 0.001, hazard ratio [HR] 5.73, 95% confidence interval [CI] 1.87–17.57; multivariable p=0.048, HR 3.45, 95% CI 1.01–11.76). In 513 patients aged ≤50 years, DMFS was significantly different as a function of DI (p=0.035, HR 3.98, 95% CI 1.00–15.89) but not RS (p=0.792). Among 376 patients aged ≤50 years who avoided chemotherapy based on low RS, 64 with high DI had worse DMFS (p=0.015, HR 5.91, 95% CI 1.17–29.78).
Conclusion
OncoFREE showed strong concordance with ODX and effectively identified high-risk patients, particularly in younger individuals. It could be an affordable alternative to ODX for guiding treatment in hormone receptor-positive early breast cancer.

730 View
127 Download

Breast cancer

Evaluation of a Direct Reverse Transcription Loop-Mediated Isothermal Amplification Method without RNA Extraction (Direct RT-LAMP) for the Detection of Lymph Node Metastasis in Early Breast Cancer: In Hee Lee, Jin Hyang Jung, Soo Jung Lee, Jeeyeon Lee, Ho Yong Park, Ji-Young Park, Jee Young Park, Jae-hwan Jung, Hyunchul Lee, Hyo-Sung Jeon, Yee Soo Chae; Cancer Res Treat. 2022;54(1):174-181. Published online April 26, 2021; DOI: https://doi.org/10.4143/crt.2020.749

Abstract PDF Supplementary Material PubReader ePub

Purpose
Assessing lymph node metastasis, tumor-derived DNA, or tumor-derived RNA has previously been studied in place of immunohistochemical assay. Because a direct reverse transcription loop-mediated isothermal amplification method (direct RT-LAMP) has been previously developed in order to rapidly identify viruses in place of RNA extraction, our team hypothesized that a direct RT-LAMP assay can be employed as a substitute in order to detect tumor involvement of lymph nodes within breast cancer patients.
Materials and Methods
A total amount of 92 lymph nodes removed across 40 patients possessing breast cancer were collected at Kyungpook National University Chilgok Hospital between the months of November 2015 and February 2016. All samples were then evaluated and contrasted via both a direct RT-LAMP assay and routine histopathologic examination.
Results
The sensitivity and specificity of the direct RT-LAMP assay were 85.7% and 100%, respectively. The positive predictive value and negative predictive value were 100% and 94.4%, respectively.
Conclusion
Direct RT-LAMP assay is capable of facilitating the detection of sentinel lymph node metastasis within breast cancer patients intraoperatively possessing an excellent sensitivity via a cost-effective and time-saving manner.

Citations

Citations to this article as recorded by

Development and evaluation of an easy to use real-time reverse-transcription loop-mediated isothermal amplification assay for clinical diagnosis of West Nile virus
Marwa Khedhiri, Melek Chaouch, Kaouther Ayouni, Anissa Chouikha, Mariem Gdoura, Henda Touzi, Nahed Hogga, Alia Benkahla, Wasfi Fares, Henda Triki
Journal of Clinical Virology.2024; 170: 105633. CrossRef
Versatility of reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) from diagnosis of early pathological infection to mutation detection in organisms
Srishti Sen, Priyanka Bhowmik, Shubhangi Tiwari, Yoav Peleg, Boudhayan Bandyopadhyay
Molecular Biology Reports.2024;[Epub] CrossRef

7,189 View
226 Download
2 Web of Science
2 Crossref

Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy: Jung Ran Choi, Jeong-Oh Kim, Dae Ryong Kang, Jung-Young Shin, Xiang Hua Zhang, Ji Eun Oh, Ji-Young Park, Kyoung-Ah Kim, Jin-Hyoung Kang; Cancer Res Treat. 2015;47(3):509-517. Published online December 16, 2014; DOI: https://doi.org/10.4143/crt.2014.012

Abstract PDF PubReader ePub

Purpose
Dose-limiting toxicities of docetaxel are widely considered to be neutropenia, anemia, skin toxicity, and nausea. One of the factors that limit the use of docetaxel is its unpredictability of inter-individual variation in toxicity. Materials and Methods In order to identify the genetic factors that affect the risk of docetaxel-induced toxicities, we recruited patients who received docetaxel chemotherapy. We genotyped 92 patients with single-nucleotide polymorphisms (SNPs) in 5 genes: CYP3A4 (CYP3A4*1B, CYP3A4*18, and CYP3A4*3), CYP3A5 (CYP3A5*2 and CYP3A5*3), ABCB1 (C1236T, G2677G/T, and C3435T), SLCO1B3 (rs11045585), and ABCC2 (rs12762549). Results Out of 92 patients, 70 had grade 3 or 4 neutropenia; 4 had grade 1 or 2; and 18 had no toxicity (76.1%, 4.3%, and 19.6%, respectively). The findings of the SNP analysis showed that patients with TT genotype of ABCB1 3435C>T polymorphism showed significantly higher risk of neutropenia and anemia (p=0.029 and p=0.044, respectively). There were significant associations between docetaxel-induced leucopenia and 2677G/T of ABCB1 and rs12762549 of ABCC2 (p=0.025 and p=0.028, respectively). In a multivariate analysis, we observed that patients carrying 2677G>T in ABCB1might be associated with higher risk of chemo-resistance when treated with docetaxel (odds ratio [OR], 6.48; confidence interval, 1.92 to 21.94; p=0.003). In a subgroup analysis of non-small cell lung cancer patients, a significant association of tumor response with G2677T/A (OR, 4.54) in ABCB1 and SLCO1B3 (OR, 9.44) was observed. Conclusion Our data suggest that ABCB1 (2677G/T) and SLCO1B3 (rs11055585) might be major genetic predictors of docetaxel-related toxicities in patients receiving docetaxel chemotherapy

Citations

Citations to this article as recorded by

Polymorphism of Transporter Genes Contributes to Variations in Treatment Outcomes and Adverse Events in Platinum Based- Chemotherapy- Treated Oral Cancer Patients
Pranab Kumar Sahoo, Tanuma Mistry, Sushmita Ghosh, Ranita Pal, Sutapa Mahata, Sinjini Sarkar, Trisha Choudhury, Sriparna Datta, R Suresh Kumar, Anup Kumar Bhowmick, Partha Nath, Kalyan Kusum Mukherjee, Vilas D. Nasare
Precision Oncogenomics.2024;[Epub] CrossRef
The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment
Xinyu Wu, Huihua Xiong
Pharmaceutics.2024; 16(11): 1407. CrossRef
Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum‐based doublet chemotherapy
Parul Sharma, Navneet Singh, Siddharth Sharma
Journal of Biochemical and Molecular Toxicology.2023;[Epub] CrossRef
Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
Yoshitaka Saito, Shinya Tamaki, Daisuke Hirate, Shinya Takada, Kenta Takahashi, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara
Scientific Reports.2023;[Epub] CrossRef
Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis
Mingrui Yan, Xiaoyu Fan, Hongyanhua Si, Xiaoyu Wang, Zhe Wang, Zhen Wang, Xin Lv, Hang Yin, Yanyan Jia, Lili Jiang, Yangliu Xia, Yong Liu
Cancer Chemotherapy and Pharmacology.2022; 89(2): 173. CrossRef
Genetic Epidemiology of Medication Safety and Efficacy Related Variants in the Central Han Chinese Population With Whole Genome Sequencing
Junbo Tian, Jing Zhang, Zengguang Yang, Shuaisheng Feng, Shujuan Li, Shiqi Ren, Jianxiang Shi, Xinyue Hou, Xia Xue, Bei Yang, Hongen Xu, Jiancheng Guo
Frontiers in Pharmacology.2022;[Epub] CrossRef
Polymorphisms in solute carrier genes ( SLC19A1 , SLCO1B1 , and SLCO1B3 ) predicts sur
Parul Sharma, Navneet Singh, Siddharth Sharma
Journal of Clinical Pharmacy and Therapeutics.2022; 47(12): 2049. CrossRef
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation
Anne T. Nies, Elke Schaeffeler, Matthias Schwab
Pharmacology & Therapeutics.2022; 238: 108268. CrossRef
Knowledge, attitude, future expectations and perceived barriers of medical students and physicians regarding pharmacogenomics in Jordan
Abdallah Alzoubi, Hashem Kanaan, Dua'a Alhazaimeh, Salam Gharaibeh, Tareq L. Mukattash, Khalid Kheirallah
International Journal of Clinical Practice.2021;[Epub] CrossRef
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel
Caterina Vivaldi, Stefania Crucitta, Silvia Catanese, Federico Cucchiara, Elena Arrigoni, Irene Pecora, Eleonora Rofi, Lorenzo Fornaro, Francesca Salani, Valentina Massa, Enrico Vasile, Riccardo Morganti, Romano Danesi, Marzia Del Re
The Pharmacogenomics Journal.2021; 21(2): 233. CrossRef
Investigation of the 1249G>A Genetic Variation of ABCC2 Drug Transporter Gene in the Turkish Population
Zuhal UCKUN SAHİNOGULLARİ
Dicle Tıp Dergisi.2021; 48(1): 72. CrossRef
Pharmacogenetics–Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort
Matias F. Martinez, Enzo Alveal, Tomas G. Soto, Eva I. Bustamante, Fernanda Ávila, Shrikant I. Bangdiwala, Ivonne Flores, Claudia Monterrosa, Ricardo Morales, Nelson M. Varela, Alison E. Fohner, Luis A. Quiñones
Frontiers in Pharmacology.2021;[Epub] CrossRef
Genetic associations of docetaxel‐based chemotherapy‐induced myelosuppression in Chinese Han population
Weihua Ren, Chenxi Zhou, Yedong Liu, Keli Su, Li Jia, Luan Chen, Mo Li, Jingsong Ma, Wei Zhou, Suli Zhang, Di Zhang, Zhiliang Cong, Xuecai Niu, Shengui Zhang, Lu Shen, Cong Huai, Xiaofang Sun, Guorong Li, Shengying Qin, Liang Guo
Journal of Clinical Pharmacy and Therapeutics.2020; 45(2): 354. CrossRef
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy
Hisanaga Nomura, Daiki Tsuji, Ken Demachi, Nobuo Mochizuki, Haruki Matsuzawa, Tomonori Yano, Hiroyuki Daiko, Satoshi Fujii, Takashi Kojima, Kunihiko Itoh, Toshikatsu Kawasaki
Cancer Chemotherapy and Pharmacology.2020; 86(2): 315. CrossRef
Association of a genetic variant in ATP‐binding cassette sub‐family B member 1 gene with poor prognosis in patients with squamous cell carcinoma of the esophagus
Azam Rastgar‐Moghadam, Mehrane Mehramiz, Soodabeh Shahidsales, Malihe Entezari, Seyed Mahdi Hassanian, Sahar Talebian, Mahnaz Nourbakhsh, Gordon A. Ferns, Amir Avan
IUBMB Life.2019; 71(9): 1252. CrossRef
Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
Rachael R. Schulte, Richard H. Ho
Molecular Pharmacology.2019; 95(5): 490. CrossRef
The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
Ruipu Sun, Ying Ying, Zhimin Tang, Ting Liu, Fuli Shi, Huixia Li, Taichen Guo, Shibo Huang, Ren Lai
Protein & Peptide Letters.2019; 27(1): 17. CrossRef
Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort
Kazuki Sone, Tetsuya Oguri, Takehiro Uemura, Akira Takeuchi, Satoshi Fukuda, Osamu Takakuwa, Ken Maeno, Kensuke Fukumitsu, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Yutaka Ito, Akio Niimi
BMC Cancer.2019;[Epub] CrossRef
Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis
Qi Jiang, Meizhen Xu, Yina Liu, Yudi Chen, Jiarong Feng, Xuelin Wang, Shuang Liang, Dan Li, Xiaoqin Yang
Cancer Chemotherapy and Pharmacology.2018; 81(2): 315. CrossRef
SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand
Raffaele Palmirotta, Claudia Carella, Erica Silvestris, Mauro Cives, Stefania Luigia Stucci, Marco Tucci, Domenica Lovero, Franco Silvestris
Oncotarget.2018; 9(38): 25355. CrossRef
Advances and challenges in hereditary cancer pharmacogenetics
Ingolf Cascorbi, Anneke Nina Werk
Expert Opinion on Drug Metabolism & Toxicology.2017; 13(1): 73. CrossRef
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients
Guillermo Gervasini, Carlos Jara, Clara Olier, Nuria Romero, Ruth Martínez, Juan Antonio Carrillo
British Journal of Clinical Pharmacology.2017; 83(3): 562. CrossRef
Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer
Delmy Oliva, Mats Nilsson, Bengt-Åke Andersson, Lena Sharp, Freddi Lewin, Nongnit Laytragoon-Lewin
Clinical and Translational Radiation Oncology.2017; 2: 1. CrossRef
Reacciones cutáneas a fármacos en el paciente con leucemia/linfoma
Mar Llamas-Velasco, Pedro Rodríguez-Jiménez, Pablo Chicharro, Javier Sánchez-Pérez
Piel.2017; 32(9): 548. CrossRef
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy
Annelot G.J. van Rossum, Marleen Kok, Danielle McCool, Mark Opdam, Nienke C. Miltenburg, Ingrid A.M. Mandjes, Elise van Leeuwen-Stok, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique M.E.M. Bos, Aart van Bochove, Erik van Werkhoven, Marjanka K. Schmidt
Oncotarget.2017; 8(69): 113531. CrossRef
Efflux Transporter Variants as Predictors of Drug Toxicity in Lung Cancer Patients: Systematic Review and Meta-Analysis
Zoulikha M Zaïr, Donald RJ Singer
Pharmacogenomics.2016; 17(9): 1089. CrossRef
Influx Transporter Variants as Predictors of Cancer Chemotherapy-Induced Toxicity: Systematic Review and Meta-Analysis
Zoulikha M Zaïr, Donald RJ Singer
Pharmacogenomics.2016; 17(10): 1189. CrossRef
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
Stefan Wolking, Elke Schaeffeler, Holger Lerche, Matthias Schwab, Anne T. Nies
Clinical Pharmacokinetics.2015; 54(7): 709. CrossRef
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
Thomas Melchardt, Clemens Hufnagl, Teresa Magnes, Lukas Weiss, Georg Hutarew, Daniel Neureiter, Alexander Schlattau, Gerhard Moser, Alexander Gaggl, Wolfgang Tränkenschuh, Richard Greil, Alexander Egle
BMC Cancer.2015;[Epub] CrossRef
Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review
C.N. Frederiks, S.W. Lam, H.J. Guchelaar, E. Boven
Cancer Treatment Reviews.2015; 41(10): 935. CrossRef

14,452 View
145 Download
34 Web of Science
30 Crossref

First
Prev
Page of 1
Next
Last

Search